AtriCure Inc. (NASDAQ:ATRC) has earned an average recommendation of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $24.80.
ATRC has been the topic of a number of research reports. Needham & Company LLC restated a “buy” rating and set a $23.00 target price (down from $25.00) on shares of AtriCure in a research report on Tuesday, January 16th. Canaccord Genuity upped their target price on shares of AtriCure from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. BidaskClub upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Friday, February 23rd. TheStreet upgraded shares of AtriCure from a “d+” rating to a “c-” rating in a research report on Friday, March 16th. Finally, ValuEngine upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Wednesday, March 7th.
AtriCure stock traded down $0.13 during trading hours on Friday, reaching $19.93. 193,911 shares of the company’s stock traded hands, compared to its average volume of 209,047. The company has a current ratio of 2.58, a quick ratio of 1.87 and a debt-to-equity ratio of 0.23. AtriCure has a fifty-two week low of $14.88 and a fifty-two week high of $25.18. The company has a market cap of $688.78, a PE ratio of -24.01 and a beta of 0.26.
AtriCure (NASDAQ:ATRC) last released its earnings results on Monday, February 26th. The medical device company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.13. AtriCure had a negative net margin of 15.39% and a negative return on equity of 16.74%. The company had revenue of $46.06 million for the quarter, compared to the consensus estimate of $45.85 million. During the same period in the prior year, the company posted ($0.27) EPS. The company’s revenue was up 11.8% compared to the same quarter last year. research analysts forecast that AtriCure will post -0.83 EPS for the current year.
In related news, SVP Justin J. Noznesky sold 4,000 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $17.03, for a total value of $68,120.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Elizabeth D. Krell sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 13th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. The disclosure for this sale can be found here. Company insiders own 10.00% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of AtriCure by 22.1% in the 4th quarter. BlackRock Inc. now owns 2,731,558 shares of the medical device company’s stock valued at $49,823,000 after acquiring an additional 494,306 shares during the period. Peregrine Capital Management LLC raised its position in shares of AtriCure by 22.7% in the 4th quarter. Peregrine Capital Management LLC now owns 1,134,406 shares of the medical device company’s stock valued at $20,692,000 after acquiring an additional 209,666 shares during the period. Victory Capital Management Inc. raised its position in shares of AtriCure by 3.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,068,895 shares of the medical device company’s stock valued at $19,497,000 after acquiring an additional 40,550 shares during the period. Neuberger Berman Group LLC raised its position in shares of AtriCure by 9.2% in the 3rd quarter. Neuberger Berman Group LLC now owns 900,296 shares of the medical device company’s stock valued at $20,140,000 after acquiring an additional 75,827 shares during the period. Finally, Citadel Advisors LLC raised its position in shares of AtriCure by 13.2% in the 4th quarter. Citadel Advisors LLC now owns 378,639 shares of the medical device company’s stock valued at $6,906,000 after acquiring an additional 44,074 shares during the period. Institutional investors and hedge funds own 87.50% of the company’s stock.
WARNING: This article was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/04/08/brokerages-set-atricure-inc-atrc-price-target-at-24-80.html.
AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.
Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.